Travere Therapeutics Stock Soars 3.6% as CEO Buys 500k Shares, Investors Eye Biotech Growth
Discover Travere Therapeutics’ latest market surge, CEO share‑buyback confidence, and 24‑hour performance vs peers—an inside look at biotech stock dynamics.
- TRAVERE THERAPEUTICS INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
4 minutes to read